Species-specific disruption of STING-dependent antiviral cellular defenses by the Zika virus NS2B3 protease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 115, Issue 27, 2018, Pages E6310-E6318

  Ding, Qiang ^a   Gaska, Jenna M ^a   Douam, Florian ^a   Wei, Lei ^a   Kim, David ^a   Balev, Metodi ^a   Heller, Brigitte ^a   Ploss, Alexander ^a  

^a PRINCETON UNIVERSITY   (United States)

Author keywords

Antiviral immunity; Flavivirus; Species tropism; Viral evasion; Zika virus

Indexed keywords

CYCLIC GMP; PROTEINASE; MEMBRANE PROTEIN; MPYS PROTEIN, HUMAN; MPYS PROTEIN, MOUSE; NS2B PROTEIN, FLAVIVIRUS; PEPTIDE HYDROLASE; VIRAL PROTEIN;

ANIMAL CELL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME DEGRADATION; GENE EXPRESSION; GENE KNOCKOUT; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; INNATE IMMUNITY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; STING GENE; VIRUS GENE; VIRUS STRAIN; ZIKA FEVER; ZIKA VIRUS; ANIMAL; CHLOROCEBUS AETHIOPS; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; PROTEIN DEGRADATION; SPECIES DIFFERENCE; VERO CELL LINE;

ANIMALS; CERCOPITHECUS AETHIOPS; HEK293 CELLS; HUMANS; IMMUNITY, INNATE; MEMBRANE PROTEINS; MICE; PEPTIDE HYDROLASES; PROTEOLYSIS; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY; VERO CELLS; VIRAL NONSTRUCTURAL PROTEINS; ZIKA VIRUS;

EID: 85049359814     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1803406115     Document Type: Article

References (58)

1. Morens DM, Fauci AS (2013) Emerging infectious diseases: Threats to human health and global stability. PLoS Pathog 9:e1003467.
2. Bhatt S, et al. (2013) The global distribution and burden of dengue. Nature 496:504–507.
3. Dick GW (1953) Epidemiological notes on some viruses isolated in Uganda; yellow fever, Rift Valley fever, Bwamba fever, West Nile, Mengo, Semliki forest, Bunyamwera, Ntaya, Uganda S and Zika viruses. Trans R Soc Trop Med Hyg 47:13–48.
4. Baud D, Gubler DJ, Schaub B, Lanteri MC, Musso D (2017) An update on Zika virus infection. Lancet 390:2099–2109.
5. Liu Y, et al. (2017) Evolutionary enhancement of Zika virus infectivity in Aedes aegypti mosquitoes. Nature 545:482–486.
6. Li C, et al. (2016) Zika virus disrupts neural progenitor development and leads to microcephaly in mice. Cell Stem Cell 19:120–126.
7. Retallack H, et al. (2016) Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci USA 113:14408–14413.
8. Govero J, et al. (2016) Zika virus infection damages the testes in mice. Nature 540: 438–442.
9. Rausch K, et al. (2017) Screening bioactives reveals nanchangmycin as a broad spectrum antiviral active against Zika virus. Cell Rep 18:804–815.
10. Barrows NJ, et al. (2016) A screen of FDA-approved drugs for inhibitors of Zika virus infection. Cell Host Microbe 20:259–270.
11. Zmurko J, et al. (2016) The viral polymerase inhibitor 7-Deaza-2′-C-methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model. PLoS Negl Trop Dis 10:e0004695.
12. Estoppey D, et al. (2017) The natural product cavinafungin selectively interferes with Zika and dengue virus replication by inhibition of the host signal peptidase. Cell Rep 19:451–460.
13. Hercík K, et al. (2017) Adenosine triphosphate analogs can efficiently inhibit the Zika virus RNA-dependent RNA polymerase. Antiviral Res 137:131–133.
14. Xu M, et al. (2016) Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat Med 22:1101–1107.
15. Richner JM, et al. (2017) Modified mRNA vaccines protect against Zika virus infection. Cell 169:176.
16. Pardi N, et al. (2017) Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543:248–251.
17. Dowd KA, et al. (2016) Rapid development of a DNA vaccine for Zika virus. Science 354:237–240.
18. Larocca RA, et al. (2016) Vaccine protection against Zika virus from Brazil. Nature 536: 474–478.
19. Abbink P, et al. (2016) Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353:1129–1132.
20. Dick GW, Kitchen SF, Haddow AJ (1952) Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg 46:509–520.
21. Newman C, Friedrich TC, O’Connor DH (2017) Macaque monkeys in Zika virus research: 1947-present. Curr Opin Virol 25:34–40.
22. Mestas J, Hughes CC (2004) Of mice and not men: Differences between mouse and human immunology. J Immunol 172:2731–2738.
23. Lazear HM, et al. (2016) A mouse model of Zika virus pathogenesis. Cell Host Microbe 19:720–730.
24. Aliota MT, et al. (2016) Characterization of lethal Zika virus infection in AG129 mice. PLoS Negl Trop Dis 10:e0004682.
25. Tripathi S, et al. (2017) A novel Zika virus mouse model reveals strain specific differences in virus pathogenesis and host inflammatory immune responses. PLoS Pathog 13:e1006258.
26. Seth RB, Sun L, Ea CK, Chen ZJ (2005) Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 122: 669–682.
27. Kawai T, et al. (2005) IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 6:981–988.
28. Xu LG, et al. (2005) VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell 19:727–740.
29. Meylan E, et al. (2005) Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437:1167–1172.
30. Ishikawa H, Barber GN (2008) STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455:674–678.
31. Zhong B, et al. (2008) The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity 29:538–550.
32. Jin L, et al. (2008) MPYS, a novel membrane tetraspanner, is associated with major histocompatibility complex class II and mediates transduction of apoptotic signals. Mol Cell Biol 28:5014–5026.
33. Sun W, et al. (2009) ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimerization. Proc Natl Acad Sci USA 106:8653–8658.
34. Crowl JT, Gray EE, Pestal K, Volkman HE, Stetson DB (2017) Intracellular nucleic acid detection in autoimmunity. Annu Rev Immunol 35:313–336.
35. Ma Z, Damania B (2016) The cGAS-STING defense pathway and its counteraction by viruses. Cell Host Microbe 19:150–158.
36. Ding Q, et al. (2013) Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity. J Hepatol 59:52–58.
37. Nitta S, et al. (2013) Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type I interferon-dependent innate immunity. Hepatology 57:46–58.
38. Aguirre S, et al. (2012) DENV inhibits type I IFN production in infected cells by cleaving human STING. PLoS Pathog 8:e1002934.
39. Stabell AC, et al. (2018) Dengue viruses cleave STING in humans but not in nonhuman primates, their presumed natural reservoir. eLife 7:e31919.
40. Yu CY, et al. (2012) Dengue virus targets the adaptor protein MITA to subvert host innate immunity. PLoS Pathog 8:e1002780.
41. Aguirre S, et al. (2017) Dengue virus NS2B protein targets cGAS for degradation and prevents mitochondrial DNA sensing during infection. Nat Microbiol 2:17037.
42. Abecasis GR, et al.; 1000 Genomes Project Consortium (2010) A map of human genome variation from population-scale sequencing. Nature 467:1061–1073, and erratum (2011) 473:544.
43. Sauer JD, et al. (2011) The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant reveals an essential function of Sting in the in vivo interferon response to Listeria monocytogenes and cyclic dinucleotides. Infect Immun 79:688–694.
44. Douam F, et al. (2015) Genetic dissection of the host tropism of human-tropic pathogens. Annu Rev Genet 49:21–45.
45. Hirai-Yuki A, et al. (2016) MAVS-dependent host species range and pathogenicity of human hepatitis A virus. Science 353:1541–1545.
46. Vogt A, et al. (2013) Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines. Virology 444:1–11.
47. Dorner M, et al. (2013) Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature 501:237–241.
48. Lazear HM, et al. (2015) Interferon-λ restricts West Nile virus neuroinvasion by tightening the blood-brain barrier. Sci Transl Med 7:284ra59.
49. Douam F, et al. (2017) Type III interferon-mediated signaling is critical for controlling live attenuated yellow fever virus infection in vivo. MBio 8:e00819-17.
50. Xia H, et al. (2018) An evolutionary NS1 mutation enhances Zika virus evasion of host interferon induction. Nat Commun 9:414.
51. Wu Y, et al. (2017) Zika virus evades interferon-mediated antiviral response through the co-operation of multiple nonstructural proteins in vitro. Cell Discov 3:17006.
52. Grant A, et al. (2016) Zika virus targets human STAT2 to inhibit type I interferon signaling. Cell Host Microbe 19:882–890.
53. Van der Hoek KH, et al. (2017) Viperin is an important host restriction factor in control of Zika virus infection. Sci Rep 7:4475.
54. Liu H, et al. (2017) Endoplasmic reticulum protein SCAP inhibits dengue virus NS2B3 protease by suppressing its K27-linked polyubiquitylation. J Virol 91:e02234-16.
55. Ishikawa H, Ma Z, Barber GN (2009) STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 461:788–792.
56. Dowall SD, et al. (2016) A susceptible mouse model for Zika virus infection. PLoS Negl Trop Dis 10:e0004658.
57. Liu B, et al. (2017) A cell-based high throughput screening assay for the discovery of cGAS-STING pathway agonists. Antiviral Res 147:37–46.
58. Piret J, Carbonneau J, Rhéaume C, Baz M, Boivin G (2018) Predominant role of IPS-1 over TRIF adaptor proteins in early innate immune response against Zika virus in mice. J Gen Virol 99:209–218.